Association Between Insulin-like Growth Factor-1 and Cardiovascular Events: a Systematic Review and Dose-response Meta-analysis of Cohort Studies

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2022 May 21

PMID 35596917

Authors

T Li

Y Zhao

X Yang

Y Feng

Y Li

Y Wu

M Zhang

X Li

H Hu

J Zhang

L Yuan

Y Liu

X Sun

P Qin

C Chen

D Hu

Affiliations

Soon will be listed here.

Abstract

Background: Insulin-like growth factor-1 (IGF-1) has increasingly been reported as linked to cardiovascular (CV) events; however, reported results have been inconsistent, and no meta-analysis has been undertaken to quantitatively assess this association.

Methods: We searched PubMed, Embase, and Web of Science databases for cohort articles published up to December 1, 2020. Fixed or random-effects models were used to estimate the summary relative risks (RRs) and 95% confidence intervals (CIs) of CV events in relation to IGF-1. Restricted cubic splines were used to model the dose-response association.

Results: We identified 11 articles (thirteen cohort studies) covering a total of 22,995 participants and 3040 CV events in this meta-analysis. The risk of overall CV events reduced by 16% from the highest to the lowest IGF-1 levels (RR 0.83, 95% CI 0.72-0.95), while the occurrence of CV events reduced by 28% (RR 0.72, 95% CI 0.56-0.92), but not for CV deaths, however (RR 1.00, 95% CI 0.65-1.55). We also found linear associations between IGF-1 levels and CV events. With each per 45 μg/mL IGF-1 increase, the pooled RRs were 0.91 (95% CI 0.86-0.96), 0.91 (95% CI 0.85-0.97) and 0.91 (95% CI 0.84-0.98) for overall CV events, for the occurrence of CV events, and for CV deaths, respectively.

Conclusions: Our findings based on cohort studies support the contention that any increase in IGF-1 is helpful in reducing the overall risk of CV events. As an important biomarker for assessing the likelihood of CV events, IGF-1 appears to offer a promising prognostic approach for aiding prevention.

Citing Articles

New insights on the cardiovascular effects of IGF-1.

Macvanin M, Gluvic Z, Radovanovic J, Essack M, Gao X, Isenovic E Front Endocrinol (Lausanne). 2023; 14:1142644.

PMID: 36843588 PMC: 9947133. DOI: 10.3389/fendo.2023.1142644.

References

Roth G, Mensah G, Johnson C, Addolorato G, Ammirati E, Baddour L . Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25):2982-3021. PMC: 7755038. DOI: 10.1016/j.jacc.2020.11.010. View

Rinderknecht E, HUMBEL R . The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978; 253(8):2769-76. View

Berelowitz M, Szabo M, Frohman L, Firestone S, Chu L, Hintz R . Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 1981; 212(4500):1279-81. DOI: 10.1126/science.6262917. View

Schutte A, Conti E, Mels C, Smith W, Kruger R, Botha S . Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study. Eur J Prev Cardiol. 2016; 23(16):1690-1699. DOI: 10.1177/2047487316661436. View

Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B . Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clin J Am Soc Nephrol. 2016; 11(7):1163-1172. PMC: 4934843. DOI: 10.2215/CJN.10441015. View

Hinojosa-Amaya J, Varlamov E, Yedinak C, Cetas J, McCartney S, Banskota S . Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort. J Endocrinol Invest. 2021; 44(12):2665-2674. DOI: 10.1007/s40618-021-01579-4. View

Parolin M, Dassie F, Vettor R, Steeds R, Maffei P . Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?. J Endocrinol Invest. 2020; 44(2):209-221. DOI: 10.1007/s40618-020-01343-0. View

Vasan R, Sullivan L, DAgostino R, Roubenoff R, Harris T, Sawyer D . Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003; 139(8):642-8. DOI: 10.7326/0003-4819-139-8-200310210-00007. View

Bleumink G, Rietveld I, Janssen J, van Rossum E, Deckers J, Hofman A . Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol. 2004; 94(3):384-6. DOI: 10.1016/j.amjcard.2004.04.044. View

10.

van Bunderen C, van Nieuwpoort I, van Schoor N, Deeg D, Lips P, Drent M . The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab. 2010; 95(10):4616-24. DOI: 10.1210/jc.2010-0940. View

11.

Ricketts S, Rensing K, Holly J, Chen L, Young E, Luben R . Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. Int J Mol Epidemiol Genet. 2011; 2(3):261-85. PMC: 3166154. View

12.

Friedrich N, Haring R, Nauck M, Ludemann J, Rosskopf D, Spilcke-Liss E . Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009; 94(5):1732-9. DOI: 10.1210/jc.2008-2138. View

13.

Jing Z, Hou X, Wang Y, Yang G, Wang B, Tian X . Association between insulin-like growth factor-1 and cardiovascular disease risk: Evidence from a meta-analysis. Int J Cardiol. 2015; 198:1-5. DOI: 10.1016/j.ijcard.2015.06.114. View

14.

Kaplan R, McGinn A, Pollak M, Kuller L, Strickler H, Rohan T . Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007; 92(4):1319-25. DOI: 10.1210/jc.2006-1631. View

16.

Kaplan R, Strizich G, Aneke-Nash C, Dominguez-Islas C, Buzkova P, Strickler H . Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. J Clin Endocrinol Metab. 2016; 102(1):267-278. PMC: 5413102. DOI: 10.1210/jc.2016-2779. View

17.

Ruidavets J, Luc G, Machez E, Genoux A, Kee F, Arveiler D . Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. Atherosclerosis. 2011; 218(2):464-9. DOI: 10.1016/j.atherosclerosis.2011.05.034. View

18.

Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T . Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002; 106(8):939-44. DOI: 10.1161/01.cir.0000027563.44593.cc. View

19.

Saydah S, Graubard B, Ballard-Barbash R, Berrigan D . Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol. 2007; 166(5):518-26. DOI: 10.1093/aje/kwm124. View

20.

Schneider H, Wallaschofski H, Volzke H, Markus M, Doerr M, Felix S . Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS One. 2012; 7(3):e33084. PMC: 3306371. DOI: 10.1371/journal.pone.0033084. View

21.

Laughlin G, Barrett-Connor E, Criqui M, Kritz-Silverstein D . The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004; 89(1):114-20. DOI: 10.1210/jc.2003-030967. View